| Literature DB >> 21153909 |
G Li1, Q Wei, Y Wang, X Du, Y Zhao, X Jiang.
Abstract
The imipenem and meropenem-resistant strains Citrobacter freundii HS70 and Escherichia coli HS510 were isolated from patients in Shanghai, China. By isoelectric focusing, PCR amplification and sequencing, these strains were each found to produce four β-lactamases: TEM-1, KPC-3, SHV-7 and CTX-M-14. A conjugation experiment and plasmid restriction digestion revealed that the bla (KPC-3) gene was located on the same plasmid in both isolates. Bidirectional primer walking sequencing showed that the nucleotide sequence surrounding the 3.8 kb bla(KPC-3) contained a 671-bp insertion similar to that previously characterized in China. The insertion was located between the promoter and the coding region of the bla(KPC-3) gene. Susceptibility testing performed on recombinant strains carrying the bla(KPC-3) gene with or without the insertion revealed that minimum inhibitory concentrations of imipenem, meropenem, cefepime, and cefotaxime for E. coli EMU-KPC3 (without insertion) were four times higher than that of E. coli EKPC3 (with insertion). The 671 bp insertion reduced bla(KPC-3) expression significantly. Taken together, these results suggest that KPC-3-producing C. freundii and E. coli have begun to emerge in our hospital.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21153909 PMCID: PMC3052496 DOI: 10.1007/s10096-010-1124-7
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
Bacterial strains and plasmids used in this study
| Strains or plasmids | Description | Reference |
|---|---|---|
| Plasmids | ||
| pACYC184 | Cloning vector | |
| pacyc184-KPC3 | Insertion of 727-2902 region between | FJ609231 |
| pMU-acyc184-KPC3 | Deletion of 1188-1706 in pacyc184-KPC3 | FJ609231 |
| pHS70 | Plasmid from E. coli J 53 (pHS70) | This study |
| pHS510 | Plasmid from E. coli J 53 (PhS510) | This study |
| Strains | ||
|
| ||
| HS70 | Clinical isolate | This study |
|
| ||
| HS510 | Clinical isolate | This study |
| E. coli J 53 (pHS70) | E. coli J53 transconjugant derived from HS70 | This study |
| E. coli J 53 (pHS510) | E. coli J53 transconjugant derived from HS510 | This study |
| EKPC3 |
| This study |
| EMU-KPC3 |
| This study |
| DH5α |
| |
| J53 |
| |
| ATCC25922 |
| |
Primers for PCR amplification of the β-lactamases genes and for cloning
| ESBL or plasmid | Primer | Sequence | Position | GenBank accession number or reference |
|---|---|---|---|---|
| KPC | KPC-F | 5′-ATGTCACTGTATCGCCGTCT-3′ | 131-150 | AF297554 |
| KPC-R | 5′-TTTTCAGAGCCTTACTGCCC-3′ | 1023-1042 | ||
| TEM | TEM-F | 5′-ATAAAATTCTTGAAGAC-3′ | 1–17 | X54604.1 |
| TEM-R | 5′-TTACCAATGCTTAATCA-3′ | 1075–1059 | ||
| SHV | SHV-F | 5′-TGGTTATGCGTTATATTCGCC-3 | 69–89 | X98100.1 |
| SHV-R | 5′-GCTTAGCGTTGCCAGTGCT-3′ | 936–918 | ||
| CTX-M-1 | M1F | 5′- GGTTAAAAAATCACTGCGTC -3 | 65–84 | X92506 |
| M1 R | 5′- TTGGTGACGATTTTAGCCGC-3 | 928–909 | ||
| CTX-M-9 | M9F | 5′-ATGGTGACAAAGAGAGTGCA-3 | 1–20 | AF252621.2 |
| M9R | 5′-CCCTTCGGCGATGATTCTC-3′ | 870–852 | ||
| M2F | 5′-ATGATGACTCAGAGCATTCG-3′ | 304–323 | ||
| CTX-M-2 | M2R | 5′-TGGGTTACGATTTTCGCCGC-3′ | 1169–1150 | AJ416343.1 |
| pacyc184-KPC3 | KPC-3 F | 5′-GCCTGGTCCGAATTCCCTCGTCATCCGCAGACCAAC-3′ | 727-747 | FJ609231 |
| KPC-3R | 5′-GCCTGGTCCGGATCCCGCGCAGACTCCTAGCCTAAA-3′ | 2882-2902 | ||
| pMU-acyc184-KPC3 | MU-KPC-3 F | 5′-CTTAACGTGAGTTTTCGTTCCACTGAGCG-3′ | 1816-1844 | FJ609231 |
| MU-KPC-3R | 5′-AAGTCATTTTTCAATATTATTGAAGCATTT ATC-3′ | 1112-1144 |
ESBL extended-spectrum beta-lactamase
Antimicrobial susceptibility patternsa
| Antimicrobial agent(s) | MIC (μg/mL) | ||||||
|---|---|---|---|---|---|---|---|
| HS70 b |
| HS510 |
| EKPC3 | EMU-KPC3 | 25922 c | |
| Imipenem | ≥128 | 2 | 16 | 2 | 8 | 32 | ≤0.0625 |
| Meropenem | ≥128 | 2 | 16 | 2 | 8 | 32 | ≤0.0625 |
| Cefepime | ≥128 | 8 | 64 | 8 | 16 | 64 | ≤0.0625 |
| Cefotaxime | ≥128 | 16 | ≥128 | 16 | 16 | 64 | ≤0.0625 |
| Ampicillin | ≥128 | ≥128 | ≥128 | ≥128 | ≥128 | ≥128 | 2 |
| Ciprofloxacin | ≥128 | ≤0.0625 | ≥128 | ≤0.0625 | ≤0.0625 | ≤0.0625 | ≤0.0625 |
| Gentamicin | ≥128 | ≤0.0625 | ≥128 | ≤0.0625 | ≤0.0625 | ≤0.0625 | ≤0.0625 |
a Minimum inhibitory concentrations (MICs) were determined by the M-H agar dilution method according to guidelines of the Clinical and Laboratory Standards Institute
b Clinical isolates: E. coli HS510 and C. freundii HS70. Transconjugants: E. coli J 53 (pHS510); E. coli J 53 (pHS70). Recombinants: EKPC3, E. coli DH5a/ pacyc184-KPC3; EMU-KPC3, E. coli DH5a/ pMU-acyc184-KPC3. Lab reference E. coli strain: 25922
c E. coli ATCC 25922 was used as quality control of antimicrobial susceptibility testing
Fig. 1Isoelectric focusing patterns of clinical isolates E. coli HS510 and C. freundii HS70. Lane 1: Cell lysate prepared from C. freundii HS70 producing TEM-1 (pI 5.4), KPC-3 (pI 6.7), SHV-12 (pI 7.6), and CTX-M-14 (pI 7.9). Lane 2: Cell lysate prepared from E. coli HS510 producing TEM-1, KPC-3, SHV-12 and CTX-M-14
Fig. 2Electrophoretic analysis of XbaI- and ClaI-digested plasmids. Lane 2: E. coli transconjugants of HS70. Lane 3: E. coli transconjugants of HS510. Marker lane: 100-bp and 1-Kb DNA ladders (Takara)
Fig. 3Schematic representation of novel genetic structure involved in bla KPC-3 gene found in bacteria isolated from Chinese patients. EU176014.1 contains ISKpn7, bla KPC-3 and ISKpn6; AM774409.1 contains ISKpn7, bla KPC-2 and ISKpn6; FJ628167 contains ISKpn8, bla KPC-2 and an ISKpn6-like element; this study contained ISKpn8, truncated β-latamase, bla KPC-3 and an ISKpn6-like element